Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Cytokinetics reported its first full quarter of MYQORZO sales on August 6. During the same three months, Armistice Capital increased its stake in the company, while several biopharma-focused hedge funds were absorbing losses on concentrated bets elsewhere in the industry. Cytokinetics reported $25.3 million in net product revenue for MYQORZO.

Read More